JP2002501033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002501033A5 JP2002501033A5 JP2000528306A JP2000528306A JP2002501033A5 JP 2002501033 A5 JP2002501033 A5 JP 2002501033A5 JP 2000528306 A JP2000528306 A JP 2000528306A JP 2000528306 A JP2000528306 A JP 2000528306A JP 2002501033 A5 JP2002501033 A5 JP 2002501033A5
- Authority
- JP
- Japan
- Prior art keywords
- neurotoxin
- composition
- type
- botulinum
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710138657 Neurotoxin Proteins 0.000 description 14
- 239000002581 neurotoxin Substances 0.000 description 14
- 231100000618 neurotoxin Toxicity 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 8
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 6
- 208000018360 neuromuscular disease Diseases 0.000 description 5
- 241000193155 Clostridium botulinum Species 0.000 description 4
- 108010055044 Tetanus Toxin Proteins 0.000 description 3
- 108010069023 botulinum toxin type E Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940118376 tetanus toxin Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1341198A | 1998-01-26 | 1998-01-26 | |
| US09/013,411 | 1998-01-26 | ||
| PCT/US1999/001526 WO1999037326A1 (en) | 1998-01-26 | 1999-01-26 | Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002501033A JP2002501033A (ja) | 2002-01-15 |
| JP2002501033A5 true JP2002501033A5 (https=) | 2006-03-23 |
Family
ID=21759834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000528306A Pending JP2002501033A (ja) | 1998-01-26 | 1999-01-26 | Ａ型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6994859B1 (https=) |
| EP (1) | EP1053014A4 (https=) |
| JP (1) | JP2002501033A (https=) |
| AU (1) | AU2340299A (https=) |
| CA (1) | CA2319113A1 (https=) |
| WO (1) | WO1999037326A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1053014A4 (en) * | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE |
| US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
| AU2001270219A1 (en) * | 2000-06-28 | 2002-01-08 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
| JP4644383B2 (ja) * | 2001-05-11 | 2011-03-02 | 日本分光株式会社 | タンパク質二次構造の面分布測定方法及び装置 |
| DE10125731A1 (de) * | 2001-05-17 | 2003-03-06 | A I D Autoimmun Diagnostika Gm | Darreichungsform von immunologischen Wirkstoffen |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| GB2419526A (en) * | 2004-10-28 | 2006-05-03 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
| GB2418358A (en) * | 2004-09-24 | 2006-03-29 | Ipsen Ltd | Pharmaceutical composition comprising botulinum neurotoxin |
| GB2416692A (en) * | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
| GB2426702A (en) * | 2004-10-28 | 2006-12-06 | Ipsen Ltd | Pharmaceutical composition comprising botulinum neurotoxin |
| GB2418359A (en) * | 2004-09-24 | 2006-03-29 | Ipsen Ltd | Pharmaceutical composition comprising botulinum neurotoxin |
| GB2419527A (en) * | 2004-10-28 | 2006-05-03 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
| US8748106B2 (en) | 2005-04-18 | 2014-06-10 | Bal Ram Singh | Methods of identifying a compound that increases or decreases the interaction of Hn-33 with synaptotagmin II |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| HUE037595T2 (hu) | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
| IL268980B (en) | 2009-06-25 | 2022-09-01 | Revance Therapeutics Inc | Albumin-free botulinum toxin formulations |
| SI2490986T1 (sl) | 2009-10-21 | 2018-12-31 | Revance Therapeutics, Inc. | Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina |
| EP2491384B1 (en) * | 2009-10-21 | 2013-12-04 | Merz Pharma GmbH & Co. KGaA | System for determining unprocessed and partially processed neurotoxin type a |
| KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| US11040090B2 (en) * | 2016-12-08 | 2021-06-22 | Prime Bio, Inc | Botulinum neurotoxin compositions |
| WO2018175696A1 (en) * | 2017-03-22 | 2018-09-27 | Bonti, Inc. | Botulinum neurotoxins for treating traumatic injuries |
| US20210121542A1 (en) * | 2019-10-28 | 2021-04-29 | Prime Bio, Inc. | Composition for delivery of protein therapeutics through oral, sublingual and buccal route |
| US12528843B2 (en) | 2020-09-17 | 2026-01-20 | Prime Bio, Inc | Pharmaceutical composition comprising P80 protein |
| EP4580666A2 (en) * | 2022-08-31 | 2025-07-09 | Evolus, Inc. | Neurotoxin compositions with increased efficacy and effect duration |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183462A (en) | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
| GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| JPH06192118A (ja) | 1992-09-28 | 1994-07-12 | Wisconsin Alumni Res Found | ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法 |
| AU683275B2 (en) | 1993-06-10 | 1997-11-06 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| DE122009000066I2 (de) | 1993-06-10 | 2010-12-30 | Allergan Inc | Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen |
| US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| DE69428813T2 (de) | 1993-12-28 | 2002-04-04 | Allergan Sales Inc | Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz |
| EP0758900B1 (en) | 1994-05-09 | 2002-04-10 | BINDER, William J. | Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN |
| JP3523879B2 (ja) | 1994-05-31 | 2004-04-26 | アレルガン インコーポレイテッド | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| EP1053014A4 (en) * | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE |
-
1999
- 1999-01-26 EP EP99903359A patent/EP1053014A4/en not_active Ceased
- 1999-01-26 AU AU23402/99A patent/AU2340299A/en not_active Abandoned
- 1999-01-26 WO PCT/US1999/001526 patent/WO1999037326A1/en not_active Ceased
- 1999-01-26 CA CA002319113A patent/CA2319113A1/en not_active Abandoned
- 1999-01-26 JP JP2000528306A patent/JP2002501033A/ja active Pending
-
2000
- 2000-04-11 US US09/546,727 patent/US6994859B1/en not_active Expired - Fee Related
-
2005
- 2005-11-22 US US11/286,515 patent/US7531183B2/en not_active Expired - Fee Related
-
2009
- 2009-05-11 US US12/463,925 patent/US9139624B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002501033A5 (https=) | ||
| KR101848095B1 (ko) | 경피 운반 | |
| EP1212093B1 (en) | Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications | |
| JP2003519666A5 (https=) | ||
| CA2332829A1 (en) | Vaccine delivery system | |
| ATE202926T1 (de) | Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung | |
| EP1824488B1 (en) | Phycotoxins and uses thereof | |
| KR20080071615A (ko) | 보툴리눔 나노에멀젼 | |
| JP2002532432A5 (https=) | ||
| CA2186673A1 (en) | The use of fatty acids in the treatment of huntington's chorea | |
| DE60138547D1 (de) | Topisch anwendbare arzneipräparate und verfahren zur behandlung | |
| EA000412B1 (ru) | Фармацевтические композиции, содержащие в качестве активного начала жизнеспособные лактобациллы, способы их применения и препарат из микроинкапсулированных лактобацилл | |
| AU2005244096B2 (en) | Transdermal administration of phycotoxins | |
| EP1383540A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR Wounds Healing | |
| JP2002523437A5 (https=) | ||
| CA2032475A1 (en) | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | |
| JP2014520892A (ja) | 脂肪沈着物を処置するための方法におけるボツリヌス毒素の使用 | |
| US7537773B1 (en) | Chemodenervating pharmaceutical as anti-inflammatory agent | |
| Baden et al. | Prophylactic and Curative Action of Trasylol® in Pancreatitis A Double-blind Trial | |
| JP2002530353A5 (https=) | ||
| Sather et al. | Pressure sores and the spinal cord injury patient | |
| JP2002535293A5 (https=) | ||
| JP2002535286A5 (https=) | ||
| JP2002529515A5 (https=) | ||
| AU7573200A (en) | Use of emu oil carrier for antifungal, antibacterial, and antiviral medications |